New publication on the future of preclinical drug development and the role of new approach methodologies (NAMs)

The FDA recently announced its plans to reduce animal testing in preclinical studies in favour of more effective, human-relevant methods, using a range of New Approach Methodologies (NAMs). To help drug developers to navigate this new paradigm, this paper outle how and when QSP (Quantitative Systems Pharmacology) among other in silico tools, can be used

16.06.2025

The FDA recently announced its plans to reduce animal testing in preclinical studies in favour of more effective, human-relevant methods, using a range of New Approach Methodologies (NAMs). To help drug developers to navigate this new paradigm, this paper outle how and when QSP (Quantitative Systems Pharmacology) among other in silico tools, can be used to phase out animal testing in a cost-efficient, timely and reliable way.